List of Oncology Medication For

Lung Cancer

The most commonly diagnosed type of lung cancer is carcinoma. There are many types of carcinoma-derived lung cancers, but the significant types are classified as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC and NSCLC are the second cancer leaders. In comparison to NSCLC, SCLC can proliferate and form solid tumor masses more rapidly. In contrast with this highly proliferative potential, SCLC is known to be less aggressive than non-small lung malignancies.

If Lung Cancer Medicines are not yet approved or available in your area, you may give a request, to get access price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

IMDELLTRA (tarlatamab-dlle) for injection

Lung Cancer, Solid Tumors

Brand Name: IMDELLTRA Generic Name: tarlatamab-dlle IMDELLTRA (tarlatamab-dlle) is used to treat adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Brand Name:	IMDELLTRA
Generic Name:	tarlatamab-dlle
Strength:	• 1 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution. • 10 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution.
Manufacturer:	Amgen Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “IMDELLTRA (tarlatamab-dlle)” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for IMDELLTRA (tarlatamab-dlle) price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

KRAZATI (adagrasib) tablets

Lung Cancer

KRAZATI (adagrasib) tablets, for oral use Initial U.S. Approval: 2022

Krazati is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) whose tumor has an abnormal KRAS G12C gene. Krazati works as a targeted therapy designed to attack the mutated KRAS protein to suppress tumor growth.

Brand Name:	KRAZATI
Generic Name:	adagrasib
Strength:	Recommended dosage: • 600 mg orally twice daily. • Swallow tablets whole with or without food.
Manufacturer:	Mirati Therapeutics, Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “KRAZATI (adagrasib) tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for KRAZATI (adagrasib) tablets price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

LAZCLUZE (lazertinib) tablets

Lung Cancer

Brand Name: LAZCLUZE Generic Name: lazertinib LAZCLUZE (lazertinib) is used to treat non-small cell lung cancer (NSCLC) .

LAZCLUZE is prescription medicines. On August 19, 2024, the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).

Brand Name:	LAZCLUZE
Generic Name:	lazertinib
Strength:	Tablets: 80 mg and 240 mg
Manufacturer:	Janssen Biotech
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “LAZCLUZE (lazertinib)” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for LAZCLUZE (lazertinib) price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Lorviqua Tablets

Lung Cancer

Lorviqua 25 mg film-coated tablets

Lorviqua (lorlatinib) is a medicine indicated for the treatment of previously treated patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The medicine is marketed in the USA under the brand name Lorbrena, and in the EU under the brand name Lorviqua. We can help you obtain Lorviqua (lorlatinib) on our website.

Facts about Lorviqua tablets

Disease Indications-Lung Cancer
Manufacturer-Pfizer Limited
Usage-Oral
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “Lorviqua tablets” based on the information you provide.

Lurbinectedin-Solution

Lung Cancer

Zepzelca 4 Mg Intravenous Solution
Alkylating Agents

Zepzelca (lurbinectedin) is a medication used for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Facts about Lurbinectedin-solution

Disease Indications-Lung Cancer
Manufacturer-Jazz Pharmaceuticals
Usage-Intravenous
Medicine Approved By-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “Lurbinectedin-solution” based on the information you provide.

Mektovi (Binimetinib) Tablets

Lung Cancer, Skin, Solid Tumors

Brand Name: Mektovi. Generic Name: (Binimetinib). It is used to treat melanoma and non-small cell lung cancer (NSCLC).

Mektovi is used in combination with another medicine, encorafenib , to treat:

melanoma (a skin cancer) that has spread or cannot be removed by surgery;
a type of lung cancer called non-small cell lung cancer (NSCLC). It is used when the cancer is advanced and has the BRAF V600E version of the mutation.

Brand Name:	Mektovi
Generic Name:	Binimetinib
Strength:	• Tablets: 15 mg.
Manufacturer:	Pfizer Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “Mektovi (Binimetinib) Tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for pharma product cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

naxitamab-gqgk injection

Lung Cancer

naxitamab-gqgk injection
for intravenous use Initial U.S. Approval: 2020

Danyelza (naxitamab-gqgk) is a medication used to treat children aged 1 year or older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Facts about naxitamab-gqgk injection

DISEASE INDICATIONS-Neuroblastoma
MANUFACTURER-Y-mAbs Therapeutics
USAGE-Intravenous
Dosage Forms and Strengths: Injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial.
MEDICINE APPROVED BY-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “naxitamab-gqgk injection” based on the information you provide.

necitumumab injection

Lung Cancer

necitumumab injection
for intravenous use Initial U.S. Approval: 2015

Portrazza (necitumumab) is a medication used for the treatment of metastatic squamous non-small cell lung cancer. This medicine has been approved in The US, Canda and Europe. We can get you the US FDA approved stock.

Facts about necitumumab injection

DISEASE INDICATIONS-Lung Cancer
MANUFACTURER-Eli Lilly Nederland B.V.
USAGE-Intravenous
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “necitumumab injection” based on the information you provide.

Nintedanib Capsules

Lung Cancer

nintedanib capsules
for oral use Initial U.S. Approval: 2014

OFEV is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Facts about nintedanib capsules

Approval Date: 2014
Proprietary Name: On Request
Active Ingredient(s): nintedanib capsules
Dosage Forms And Strengths: Capsules: 150 mg and 100 mg
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Current indications: idiopathic pulmonary fibrosis (IPF).
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “nintedanib capsules” based on the information you provide.

Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection

Kidney, Chronic Disease, Colon, Esophageal, Gastrointestinal, Head And Neck, Lung Cancer, Solid Tumors, Urothelial Carcinoma

Brand Name: Opdivo Qvantig. Generic Name: (nivolumab and hyaluronidase-nvhy). It is used to treat Renal Cell Carcinoma (RCC), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Carcinoma (UC), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma..

OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of Renal Cell Carcinoma (RCC), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Carcinoma (UC), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Esophageal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.

Brand Name:	Opdivo Qvantig
Generic Name:	nivolumab and hyaluronidase-nvhy
Strength:	• Injection: 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/2,000 units per mL) in a single-dose vial.
Manufacturer:	Bristol-Myers Squibb
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for pharma product cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

« Older Entries

Next Entries »

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query Form For Medications

Note

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Disclaimer

“Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in is intended to provide general information about consultancy services offered by IPN and to help users access this information in a user friendly format. Certain information available on the website has been sourced from publicly available sources. While Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in believes such information to be reasonably accurate, Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in has not independently verified any of this information. All information on the IPN website is of general nature and is not a substitute for medical prescription. None of the medicines or products mentioned on the IPN website are manufactured or sold by IPN Pharma Network.

Privacy Policy

Please read the following statement to learn about our information gathering and dissemination practices in relation to our consultancy services (“Services”). Note: Our privacy policy is subject to change at any time without notice. To make sure you are aware of any changes, please review this policy periodically. By visiting the Indian Pharma Network

Health Information

“All information available on the Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in is of general nature and is not a substitute for professional medical advice by a licensed practitioner. Indian Pharma Network (IPN) does not purport to provide any medical or health-related advice, even of general nature and therefore you should not use or consult the Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in for any questions in relation to your health or medical condition.

Shipped Anti-Cancer Medicines.

Indian Pharma Network is registered medical pharmacy for Oncology Products in India. Helps you to access FDA approved Anti-Cancer-Medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery. We have helped more than 6,000 patients. Send your enquiry to find the What is the cost of Anti Cancer Medicines in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Lung Cancer

Brand Name: IMDELLTRA Generic Name: tarlatamab-dlle IMDELLTRA (tarlatamab-dlle) is used to treat adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

KRAZATI (adagrasib) tablets, for oral use Initial U.S. Approval: 2022

Brand Name: LAZCLUZE Generic Name: lazertinib LAZCLUZE (lazertinib) is used to treat non-small cell lung cancer (NSCLC) .

Lorviqua 25 mg film-coated tablets

Facts about Lorviqua tablets

Access the best support services globally

Zepzelca 4 Mg Intravenous Solution Alkylating Agents

Access the best support services globally

Brand Name: Mektovi. Generic Name: (Binimetinib). It is used to treat melanoma and non-small cell lung cancer (NSCLC).

naxitamab-gqgk injection for intravenous use Initial U.S. Approval: 2020

Facts about naxitamab-gqgk injection

Access the best support services globally

necitumumab injection for intravenous use Initial U.S. Approval: 2015

Facts about necitumumab injection

Access the best support services globally

nintedanib capsules for oral use Initial U.S. Approval: 2014

Facts about nintedanib capsules

Access the best support services globally

Contact Info

Query Form For Medications

Note

Disclaimer

Privacy Policy

Health Information

Shipped Anti-Cancer Medicines.

Indian Pharma Network (IPN), New Delhi. India

Zepzelca 4 Mg Intravenous Solution
Alkylating Agents

naxitamab-gqgk injection
for intravenous use Initial U.S. Approval: 2020

necitumumab injection
for intravenous use Initial U.S. Approval: 2015

nintedanib capsules
for oral use Initial U.S. Approval: 2014